期刊文献+

EB病毒感染的免疫血清学检测与生物学测定在鼻咽癌中的临床应用价值 被引量:2

下载PDF
导出
摘要 目的探讨和评价4种最常用的EB病毒抗体及EBV-DNA含量在鼻咽癌中的临床应用价值,并探讨单独检测以何者为优良,以及采用何种组合在鼻咽癌的早期诊断、临床分期,疗效监测、转移、复发和预后判断中为最客观、最具代表性和最有效的组合。方法应用ELISA方法检测4种最常用的EB病毒抗体以及应用荧光定量PCR方法检测血浆EBV-DNA含量。结果血浆EBV-DNA,血清学的EBNA1-IgA敏感度、特异度最高;4种最常用的EB病毒抗体和EBV-DNA鼻咽癌组分别与鼻息肉组、慢性鼻咽炎组、颈部淋巴结炎组及正常成年人对照组阳性人群的比较差异有显著统计学意义(P<0.01);但与头颈部恶性淋巴瘤组差异无统计学意义(P>0.05);EBNA1-IgA、Zta-IgA、EBV-DNA联合检测的临床应用价值最高。结论 EB病毒抗体及EBV-DNA在鼻咽癌临床应用上具有重要价值。
出处 《海南医学》 CAS 2011年第15期105-107,共3页 Hainan Medical Journal
  • 相关文献

参考文献8

  • 1Macswecn KF, Crawford DH. Epstein-Ban- Vires-recent advance [J]. Lancet Infect Dis, 2003, 3(3): 131-140.
  • 2邓洪,曾毅,郑裕明,梁建平,廖建,周微雅,黄碧珍,成积儒,钟建明.自然人群413164人鼻咽癌血清学普查[J].中国癌症杂志,2003,13(2):109-111. 被引量:37
  • 3Henle G, Henle W. EBV-specific IgA serum antibodies as an out- standing feature ofNPC [J]. Int J Cancer, 1976, 17: 1-7.
  • 4李锦添 宗永生.鼻咽癌的病理改变与血清中EBVVcA-IgA抗体滴度的关系.中华病理杂志,1986,(15):122-125.
  • 5Zong YS, Sham JS, Ng MH, ct al. Immunoglobulin A against Viral Capsid antigen of Epstein" Barr Virus and indirect mirror examina- tion of the nasopharynx in the detection of asymptomatic nasopha- ryngeal carcinoma [J]. Cancer, 1992, 69: 3-7.
  • 6Hsh MM, Hsu WC, Sheen TS, et al. Specific IgA antibodies to re- combinant early and nuclear antigens of Epsteirr-Barr virus in naso- pharyngeal carcinoma [J]. Clin otolaryngol, 2001, 26(4): 334.
  • 7李宇红,邵建永,冯惠霞,郜红艺,张力,管忠震,曾益新.鼻咽癌患者血浆游离EBV/DNA的定量检测及其临床意义[J].中国肿瘤临床,2004,31(8):421-424. 被引量:37
  • 8Dardari R, Hinderer W, Lang D, et al. Antibody responses to recom- binant Epsteirr-Barr Virus antigens in nasopharyngeal carcinoma: Complementary test of ZEBRA protein and carly antigens P54 and P138 [J]. Clin Microbiol, 2001, 39(39): 3164-3170.

二级参考文献16

  • 1刘泰福,徐国镇.全国鼻咽癌会议纪要[J].中华放射肿瘤学杂志,1992,0(4):5-10. 被引量:132
  • 2邓洪,赵正宝,张政,皮至明,李秉均,廖建,黎而介,李可能,胡良芬,银佑长,王培中,曾毅.广西21市县338868人鼻咽癌血清学普查[J].中华预防医学杂志,1995,29(6):342-343. 被引量:10
  • 3曾毅.鼻咽癌病因研究[J].中国肿瘤,1996,5(5):8-8. 被引量:26
  • 4[2]Lo YM, Chan LY, Lo KW, et al. Quantitative analysis of cellfree Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma[J]. Cancer Res, 1999, 59(6):1188~1191
  • 5[3]Anker P, Mulcahy H, Chen XQ, et al. Detection of circulating tumor DNA in blood (plasma/serum) of cancer patients[J]. Cancer Metastasis Rev, 1999, 18(1): 65~73
  • 6[4]Mutirangura A, Pomthanakasem W, Theamboonlers A, et al.Epstein-Barr viral DNA in serum of patients in nasopharyngeal carcinoma[J]. Clin Cancer Res, 1998, 4(3): 665~669
  • 7[5]Shotelesuk K, Khorprasert C, Sakdikul S, et al. Epstein-Bart viral DNA in serum/plasma as a tumor marker for nasopharyngeal carcinoma[J]. Clin Cancer Res, 2000, 6(3): 1046~1051
  • 8[6]Lo YM, Leung SF, Chan LY, et al. Kinetics of plasma EpsteinBarr virus DNA during radiation therapy for nasopharyngeal carcinoma[J]. Cancer Res, 2000, 60(9): 2351~2355
  • 9[8]Lo YM, Chan AT, Chan LY, et al. Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Bart virus DNA [J]. Cancer Res, 2000, 60 (24): 6878~6881
  • 10[9]Chant AT, Lo YM, Zee B, et al. Plasma Epstein-Bart virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma [J]. J Natl Cancer Inst, 2002, 94 (21):1614~1619

共引文献70

同被引文献15

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部